title: Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.
abstract: OBJECTIVE
  To identify changes in hepatic parenchymal volume, fibrosis, and induction of portal hypertension following radioembolization with glass microspheres for patients with metastatic disease to the liver.
  
  
  RESULTS
  In our series of sequential bilobar (n = 17) treatments, a mean decrease in liver volume of 11.8% was noted. In this group, a mean splenic volume increase of 27.9% and portal vein diameter increase of 4.8% were noted. For patients receiving unilobar treatments (n = 15), mean ipsilateral lobar volume decrease of 8.9%, contralateral lobar hypertrophy of 21.2%, and a 5.4% increase in portal vein diameter were also noted. These findings were not associated with clinical toxicities.
  
  
  CONCLUSIONS
  (90)Yttrium radioembolization utilizing glass microspheres in patients with liver metastases results in changes of hepatic parenchymal volume and also induced findings suggestive of fibrosis and portal hypertension. Further studies assessing the long-term effects are warranted.
authors.affiliation: Department of Radiology, Ludwig-Maximilians-University of Munich, Campus Grosshadern, Marchioninistrasse 15, Munich, Germany.
authors.forename: T F
authors.initials: TF
authors.lastname: Jakobs
authors.forename: S
authors.initials: S
authors.lastname: Saleem
authors.forename: B
authors.initials: B
authors.lastname: Atassi
authors.forename: E
authors.initials: E
authors.lastname: Reda
authors.forename: R J
authors.initials: RJ
authors.lastname: Lewandowski
authors.forename: V
authors.initials: V
authors.lastname: Yaghmai
authors.forename: F
authors.initials: F
authors.lastname: Miller
authors.forename: R K
authors.initials: RK
authors.lastname: Ryu
authors.forename: S
authors.initials: S
authors.lastname: Ibrahim
authors.forename: K T
authors.initials: KT
authors.lastname: Sato
authors.forename: L M
authors.initials: LM
authors.lastname: Kulik
authors.forename: M F
authors.initials: MF
authors.lastname: Mulcahy
authors.forename: R
authors.initials: R
authors.lastname: Omary
authors.forename: R
authors.initials: R
authors.lastname: Murthy
authors.forename: M F
authors.initials: MF
authors.lastname: Reiser
authors.forename: R
authors.initials: R
authors.lastname: Salem
mesh_terms: D018450:Disease Progression; D004307:Dose-Response Relationship, Radiation; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D006975:Hypertension, Portal / Q000209:etiology*; D008099:Liver / Q000254:growth & development* / Q000473:pathology / Q000528:radiation effects; D008103:Liver Cirrhosis / Q000209:etiology*; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary*; D008297:Male; D008863:Microspheres; D009929:Organ Size / Q000528:radiation effects; D011832:Radiation Injuries / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects* / Q000379:methods; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D015021:Yttrium Radioisotopes